Objective To explore the therapeutic effect of the combination of fosinopril sodium and doxazosin on renal hypertension,and to analyze the blood pressure control and changes in related active factors in patients after treatment.Methods A prospective study was conducted on 98 patients with renal hypertension admitted to Beichen Hospital from October 2020 to October 2023.Random number table method was used as the grouping method,and they were divided into an observation group(n=49)and a control group(n=49).The control group patients were treated with fosinopril sodium,while the observation group was treated with doxazosin additionally.The blood pressure control effect,changes in levels of NO,ET,Ang Ⅱ related bioactive factors,renal function changes before and after treatment,and their adverse reactions were compared.Results The total response rate in the observation group was 89.79％,which was higher than 73.47％in the control group(χ2=4.356,P=0.037).Ang Ⅱ and ET levels in both groups decreased after treatment,the observation group[(13.62±2.24)ng/mL,(68.62±6.66)ng/L]was lower than the control group[(16.25±4.32)ng/mL,(74.26±9.35)ng/L],the difference was statistically significant(t1=3.783,t2=3.439,P<0.001).Elevated NO levels in the observation group[(54.26±3.42)μmol/L]was higher than the control group[(50.51±2.37)μmol/L],the difference was statistically significant(t=6.309,P<0.001).Blood Scr,BUN,and CysC levels were decreased in both treatment groups,and those in observation group[(404.36±92.12)μmoI/L,(13.34±4.31)mmol/L,(2.19±0.24)mg/L]were lower than the control group[(443.49±80.19)μmoI/L,(15.07±4.23)mmol/L,(2.87±0.38)mg/L],the differences were statistically significant(t1=2.243,P1=0.027;t2=2.005,P2=0.048;t3=10.591,P3<0.001;P<0.05).There was no difference in the incidence of adverse effects between the two groups(10.20％vs 8.16％,P>0.05).Conclusions The combination treatment of fosinopril sodium and doxazosin can improve the blood pressure control effect,improve endothelial function,reduce the expression level of angiotensin Ⅱ,and improve renal function in patients with renal hypertension,with high safety.
维普
万方数据